0001493152-23-030131.txt : 20230825 0001493152-23-030131.hdr.sgml : 20230825 20230825061536 ACCESSION NUMBER: 0001493152-23-030131 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230824 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230825 DATE AS OF CHANGE: 20230825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRxADE HEALTH, INC CENTRAL INDEX KEY: 0001382574 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39199 FILM NUMBER: 231203754 BUSINESS ADDRESS: STREET 1: 2420 BRUNELLO TRACE CITY: LUTZ STATE: FL ZIP: 33558 BUSINESS PHONE: (800) 261 0281 MAIL ADDRESS: STREET 1: 2420 BRUNELLO TRACE CITY: LUTZ STATE: FL ZIP: 33558 FORMER COMPANY: FORMER CONFORMED NAME: TRXADE GROUP, INC. DATE OF NAME CHANGE: 20140207 FORMER COMPANY: FORMER CONFORMED NAME: XCELLINK INTERNATIONAL INC. DATE OF NAME CHANGE: 20081230 FORMER COMPANY: FORMER CONFORMED NAME: Bluebird Exploration Co. DATE OF NAME CHANGE: 20061204 8-K 1 form8-k.htm
0001382574 false 0001382574 2023-08-24 2023-08-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): August 24, 2023

 

TRxADE HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39199   46-3673928

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2420 Brunello Trace, Lutz, Florida   33558
(Address of principal executive offices)   (Zip Code)

 

(800) 261-0281

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock, par value $0.00001 per share   MEDS   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events.

 

On August 24, 2023, Superlatus, Inc. (the “Company”), with a subsidiary of TRxADE HEALTH, Inc. (NASDAQ: MEDS) issued a press release announcing its intent to introduce pulse-based twisted protein snacks through its Brave Robot Brand. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein solely for purposes of this Item 8.01 disclosure.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about the Company and its industry, beliefs and assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to the following: agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; and the areas detailed in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

 

Item 9.01. Financial Statements and Exhibits

 

Exhibit No.   Description of Exhibit
99.1   Press Release, Dated August 24, 2023
104   Inline XBRL for the cover page of this Current Report on Form 8-K

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TRxADE HEALTH, INC.
     
  By: /s/ Suren Ajjarapu
  Name: Suren Ajjarapu
  Title: Chief Executive Officer
     
Dated: August 25, 2023    

 

 

 

 

EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

A picture containing text, font, logo, graphics

Description automatically generated

 

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

 

TAMPA, FL, Aug. 24, 2023 –Superlatus Inc. (‘Superlatus’ or the ‘Company’) recently merged with TRxADE HEALTH, Inc. (NASDAQ: MEDS) and is gearing up to revolutionize the snack industry. The Company has unveiled its intent to introduce pulse-based twisted protein snacks through its Brave Robot brand. This disruptive innovation leverages the advanced food extrusion technology from Sapientia Technology, LLC (‘Sapientia’), a wholly-owned subsidiary of the Company.

 

Superlatus’ subsidiaries operate complementary businesses and exhibit synergies; the Company has designed the overall growth and expansion strategy to leverage these inherent advantages to generate superior returns, drive growth, and enhance competitiveness. To exploit the combined power of unique food technology developed by well-known scientist Dr. Gino Bortone, inventor of Cheetos Frito-Lay’s Twisted Cheetos, and to leverage the widespread popularity and distribution of the Brave Robot brand, the Company expects to be successful in the snack food sector, projected to be worth a staggering $736 billion by 2026.

 

Serving as Superlatus’ Chief Technology Officer, Dr. Eugenio Bortone’s credentials are unmatched. As an acclaimed food scientist and extrusion specialist, he’s credited with four pioneering patents focusing on the unique shape and texture of “protein curls” and crispy puff-style snacks. During his tenure at Frito Lay, Dr. Bortone was the brain behind several blockbuster products, including the iconic Twisted Cheetos.

 

“Over 100,000 schools and institutions serve school lunches to 29.6 million students daily. We know soft drinks and traditional chips are the most frequent items sold in vending machines at school,” said Superlatus interim CEO Tim Alford. “By dominating and leading the better-for-you (BFY) snack category in the schools, colleges, and universities across the continental United States, we have the unique opportunity to grow rapidly as our products have a long shelf-life, no chemicals, and there are no freezing costs.”

 

The pulse-based twisted protein snack under the Brave Robot portfolio will be well-positioned to solve the problem of empty calories with tasty snacks. When compared to traditional snacks, it will have 25% less calories (112 calories), over 300% more protein (8 g), 200% fiber (3 g), 40% less fat (6 g), 67% less saturated fat (0.5 g), 20% less sodium (200 mg), at an affordable price point of less than $2.00 per bag. As a proof of concept, The pulse-based twisted protein snacks are already being sold in 300 Federated Co-Operatives in Canada under different private labels. The Company expects to market the Brave Robot snacks in the United States in early 2024.

 

About The Urgent Company

 

The Urgent Company is a new type of CPG company with a singular focus on the next generation of consumer brands that harness the latest in innovation and science to create revolutionary, delicious, and sustainable animal-free foods with less impact on the planet. The Urgent Company made its marketplace premiere with the launch of Brave Robot, a revolutionary ice cream made with Perfect Day’s non-animal whey protein, which uses science and a little bit of technology to remove animals from the equation without sacrificing the indulgent taste and texture of dairy. Visit The Urgent Company to learn more.

 

About Brave Robot

 

Brave Robot is the premier brand from The Urgent Company, a new type of CPG company with a singular focus on discovering new applications for science and technology that make better, more sustainable products, starting with food. Unlike plant-based alternatives that don’t taste like dairy, Brave Robot is evolving how ice cream is made to be sustainable and delicious. Made with animal-free whey protein from Perfect Day, Brave Robot isn’t like dairy. It is dairy, just without the cow - meaning it’s also lactose-free and vegan-friendly. Visit Brave Robot to learn more.

 

 

 

 

About Superlatus, Inc.

 

Superlatus is a diversified food technology company with distribution capabilities. We scale food innovation and transformational change to our food systems to optimize food security and population health via innovative CPG products, agrotech, food tech, plant-based proteins, and alt-proteins. We provide industry-leading processing and forming technologies that create high-nutrition, high-taste, and textured foods. Our management team comprises world-class food executives with an unparalleled understanding of technology and taste. For more information on Superlatus, please visit Superlatus to learn more.

 

About TRxADE HEALTH, INC.

 

TRxADE HEALTH (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the US. The Company operates the TRxADE drug procurement marketplace serving approximately 14,500+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. The Company plans to exit the health services IT business. For more information on TRxADE HEALTH, please visit the Company’s IR website at investors.trxadegroup.com.

 

Forward-Looking Statements

 

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our Company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in TRxADE’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

 

Forward-looking statements speak only as of the date they are made. The TRxADE undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

 

Investor Contact:

 

Skyline Corporate Communications Group, LLC

Scott Powell, President

One Rockefeller Plaza, 11th Floor

New York, NY 10020

Office: (646) 893-5835

Email: info@skylineccg.com

 

 

 

 

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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meds-20230824.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 meds-20230824_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 meds-20230824_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 24, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 24, 2023
Entity File Number 001-39199
Entity Registrant Name TRxADE HEALTH, INC.
Entity Central Index Key 0001382574
Entity Tax Identification Number 46-3673928
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2420 Brunello Trace
Entity Address, City or Town Lutz
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33558
City Area Code (800)
Local Phone Number 261-0281
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol MEDS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001382574 2023-08-24 2023-08-24 iso4217:USD shares iso4217:USD shares 0001382574 false 8-K 2023-08-24 TRxADE HEALTH, INC. DE 001-39199 46-3673928 2420 Brunello Trace Lutz FL 33558 (800) 261-0281 false false false false Common Stock, par value $0.00001 per share MEDS NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://trxadehealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm meds-20230824.xsd meds-20230824_lab.xml meds-20230824_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "meds-20230824_lab.xml" ] }, "presentationLink": { "local": [ "meds-20230824_pre.xml" ] }, "schema": { "local": [ "meds-20230824.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MEDS", "nsuri": "http://trxadehealth.com/20230824", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://trxadehealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-030131-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-030131-xbrl.zip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end